Wave Life Sciences, Inc. (WVE) stock
WVENasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 10/3050% below fair value
$2.56−0.16 (-5.88%)
Close on Nov 20, 2026Market cap $504.91MP/E –Yield –
Wave Life Sciences free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Wave Life Sciences's free cash flow for the twelve months ending Sep 30, 2026 was -$208.39M. For fiscal 2025 it was -$188.21M. The highest annual figure on record is -$3.60M in fiscal 2013.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$188.21M | – |
| FY2024 | Dec 31, 2024 | -$151.96M | – |
| FY2023 | Dec 31, 2023 | -$20.55M | – |
| FY2022 | Dec 31, 2022 | -$129.14M | – |
| FY2021 | Dec 31, 2021 | -$89.55M | – |
| FY2020 | Dec 31, 2020 | -$117.32M | – |
| FY2019 | Dec 31, 2019 | -$192.15M | – |
| FY2018 | Dec 31, 2018 | -$32.80M | – |
| FY2017 | Dec 31, 2017 | -$102.56M | – |
| FY2016 | Dec 31, 2016 | -$37.49M | – |
| FY2015 | Dec 31, 2015 | -$14.38M | – |
| FY2014 | Dec 31, 2014 | -$5.02M | – |
| FY2013 | Dec 31, 2013 | -$3.60M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$60.16M | – |
| Q2 FY2026 | Jun 30, 2026 | -$54.47M | – |
| Q1 FY2026 | Mar 31, 2026 | -$59.99M | – |
| Q4 FY2025 | Dec 31, 2025 | -$33.78M | – |
| Q3 FY2025 | Sep 30, 2025 | -$44.91M | – |
| Q2 FY2025 | Jun 30, 2025 | -$46.32M | – |
| Q1 FY2025 | Mar 31, 2025 | -$63.20M | – |
| Q4 FY2024 | Dec 31, 2024 | -$43.73M | – |
| Q3 FY2024 | Sep 30, 2024 | -$46.86M | – |
| Q2 FY2024 | Jun 30, 2024 | -$27.52M | – |
| Q1 FY2024 | Mar 31, 2024 | -$33.85M | -139.8% |
| Q4 FY2023 | Dec 31, 2023 | -$33.60M | – |
| Q3 FY2023 | Sep 30, 2023 | -$34.66M | – |
| Q2 FY2023 | Jun 30, 2023 | -$37.33M | – |
| Q1 FY2023 | Mar 31, 2023 | $85.03M | – |
| Q4 FY2022 | Dec 31, 2022 | -$33.64M | – |
| Q3 FY2022 | Sep 30, 2022 | -$26.10M | – |
| Q2 FY2022 | Jun 30, 2022 | -$29.31M | – |
| Q1 FY2022 | Mar 31, 2022 | -$40.08M | – |
| Q4 FY2021 | Dec 31, 2021 | -$7.05M | – |
| Q3 FY2021 | Sep 30, 2021 | -$28.28M | – |
| Q2 FY2021 | Jun 30, 2021 | -$9.74M | – |
| Q1 FY2021 | Mar 31, 2021 | -$44.48M | – |
| Q4 FY2020 | Dec 31, 2020 | -$31.97M | – |
| Q3 FY2020 | Sep 30, 2020 | -$20.24M | – |
| Q2 FY2020 | Jun 30, 2020 | -$38.28M | – |
| Q1 FY2020 | Mar 31, 2020 | -$26.83M | – |
| Q4 FY2019 | Dec 31, 2019 | -$62.59M | – |
| Q3 FY2019 | Sep 30, 2019 | -$44.15M | – |
| Q2 FY2019 | Jun 30, 2019 | -$34.53M | -149.7% |
| Q1 FY2019 | Mar 31, 2019 | -$50.89M | – |
| Q4 FY2018 | Dec 31, 2018 | -$36.28M | – |
| Q3 FY2018 | Sep 30, 2018 | -$32.40M | – |
| Q2 FY2018 | Jun 30, 2018 | $69.47M | – |
| Q1 FY2018 | Mar 31, 2018 | -$33.59M | – |
| Q4 FY2017 | Dec 31, 2017 | -$26.83M | – |
| Q3 FY2017 | Sep 30, 2017 | -$29.02M | – |
| Q2 FY2017 | Jun 30, 2017 | -$25.66M | – |
| Q1 FY2017 | Mar 31, 2017 | -$21.05M | – |
| Q4 FY2016 | Dec 31, 2016 | -$16.08M | – |
See a number that looks wrong?